http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2021152057-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3cd3ea6c52ef8544c67c051a2ef489b3 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-47 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-38 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-32 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-06 |
| filingDate | 2021-06-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b36fab1966bccba83e9d2c027b0554ac |
| publicationDate | 2021-09-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2021152057-A |
| titleOfInvention | Medicine |
| abstract | PROBLEM TO BE SOLVED: To provide a pharmaceutical product using a solid preparation in which lactone formation of pitavastatin or a salt thereof is suppressed. The following components (A) and (B): (A) Pitavastatin or a salt thereof; (B) One or more selected from the group consisting of carmellose and its salts, crospovidone and crystalline cellulose; This is a pharmaceutical product in which an orally disintegrating tablet containing 2.9% by mass or less of water is contained in an airtight package. [Selection diagram] None |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2020163059-A |
| priorityDate | 2019-10-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 102.